The LPL agonist decreased SCLC risk via ApoB (OR 0.20, 95% CI 0.07–0.58, p = 0.012) and TG reduction (OR 0.58, 95% CI 0.43–0.77, p = 0.003) while increased the plasma S1P level. The gene discussed is LPL; the disease is small cell lung carcinoma.